Literature DB >> 9024065

T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings.

D M Dorfman1, J A Longtine, E A Fox, D S Weinberg, G S Pinkus.   

Abstract

T-cell blast crisis in chronic myelogenous leukemia is rare. We examined three patients (ages 35 to 72 years) in whom T-cell blast crisis developed 11 to 36 months (mean, 25 months) after diagnosis of chronic myelogenous leukemia and who died 4 to 12 months (mean, 7 months) thereafter. Two patients had diffuse lymphadenopathy, and the third had marked lymphocytosis (white blood cell count 217,000/microL, with 90% circulating blasts). In all three patients, neoplastic cells had the appearance of lymphoblasts and were immunoreactive for T-cell markers by immunohistochemical or flow cytometric analysis or both. Molecular diagnostic studies revealed the presence of a bcr-abl oncogene rearrangement in all three cases, but none exhibited a clonal T-cell receptor delta, beta, or gamma chain gene rearrangement. One case exhibited deletion of the J delta 1 region of both delta chain genes. The significance of these findings is discussed, and they are compared with those of other reported cases of T-cell blast crisis in chronic myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024065     DOI: 10.1093/ajcp/107.2.168

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis.

Authors:  Fernando Abollo-Jiménez; Elena Campos-Sánchez; Amparo Toboso-Navasa; Carolina Vicente-Dueñas; Inés González-Herrero; Esther Alonso-Escudero; Marcos González; Víctor Segura; Oscar Blanco; José Angel Martínez-Climent; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

2.  Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

Authors:  Preetesh Jain; Hagop Kantarjian; Elias Jabbour; Rashmi Kanagal-Shamanna; Keyur Patel; Sherry Pierce; Guillermo Garcia-Manero; Gautam Borthakur; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Am J Hematol       Date:  2016-11-18       Impact factor: 10.047

3.  Philadelphia chromosome-negative non-Hodgkin's lymphoma occurring in Philadelphia chromosome-positive chronic myeloid leukemia: A case report and literature review.

Authors:  Zheng-Lei Shen; Lie-Fen Yin; Wen-Wen Mao; Jin Liang; Ling Yang
Journal:  Oncol Lett       Date:  2016-03-07       Impact factor: 2.967

Review 4.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.